The contract development and manufacturing organisation (CDMO) has added the Leganés, Spain solid dose manufacturing plant to its network after coming to an agreement with former owner Roche.
While financial details have not been divulged, a long-term contract agreement between the firms will add approximately €35m ($42m) to Recipharm’s annual sales – equating to more than 6% of the CDMO’s total revenue – from the manufacture of a range of solid dose products from the facility for Roche.
According to Recipharm CEO Thomas Eldered, solid dose formulation was already the firm’s largest business segment before the acquisition but with the Leganés facility the firm will now operate eight solid dose facilities.
“Our ambition is to continue offer competitive services in this area,” he told in-Pharmatechnologist.
The added facility will also offer opportunity for collaboration with Recipharm’s facility near Barcelona, Spain.
“We have a pretty full range service offering but we are looking for some further niche technologies. We are continuously evaluating additions that would be beneficial for our customers.”
The Leganés site, located near Madrid, was one of a number put up for sale by Roche in November 2015 as part of a plan to reduce its small molecule manufacturing footprint.
In June 2016, Greek CDMO Famar struck a deal with Roche to buy the plant but this subsequently fell through.
Earlier this month, Italian CMO Delpharm completed its acquisition of Roche’s solid and liquid forms manufacturing facility in Milan/Segrate, Italy and – like Recipharm today – inked a supply contract with the Swiss pharma giant.